The adverse events associated with ruxolitinib therapy in MPNs suggests that similar clinical challenges will be observed when incorporating ruxolitinib into treatment approaches for JAK2-altered ALL. The gene discussed is JAK2; the disease is acute lymphoblastic leukemia.